| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
SCCKN and alpha2-AP transfectants were subcutaneously inoculated into the nude mice. E-cadherin on cell membrane of xenograft from alpha2-AP transfectants was increased compared to SCCKN. Moreover, beta-catenin increased on cell membrane of xenograft from alpha2-AP transfectants.
These findings suggest that the suppression of the plasminogen activator/plasmin system by alpha2-AP might reduce the dissemination of OSCC cells. Therefore, it could be expected the development of gene therapy for invasiveness and metastasis of OSCC cells with induction of alpha2-AP into OSCC tissue.
|
